Clinical trials: Recurrent Myeloproliferative Neoplasm
- Condition Recurrent Myeloproliferative Neoplasm
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
This is an open-label, non-randomized, Phase 1 study to determine the safety and tolerability of NC525. This study will also assess the clinical benefit in subjects with advanced myeloid neoplasms.
- Conditions
- Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia, Relapsed or Refractory Myelodysplastic Syndrome
- Trial name
- NCT05787496
- Testing
- NC525
- Where
- 11 sites in United States
- Volunteers
- 28 people
- Sponsor
- NextCure, Inc.
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Acute Myeloid Leukemia, Leukemia
A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status
Patients received oral AC220 daily for 14 days to study the side effects, tolerability and best dose for treating relapsed or refractory acute myeloid leukemia, regardless of FLT3 status.
- Conditions
- Acute Myeloid Leukemia, Leukemia, Myelodysplastic Syndrome, AML
- Trial name
- NCT00462761
- Testing
- AC220
- Where
- 5 sites in United States, Georgia
- Volunteers
- 76 people
- Sponsor
- Daiichi Sankyo
Myelofibrosis
Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor
The purpose of this study is to evaluate the efficacy and safety of 2 dose regimens of imetelstat in participants with intermediate-2 or high-risk myelofibrosis (MF) whose disease is relapsed after or is refractory to Janus…
- Trial name
- NCT02426086
- Testing
- Imetelstat 4.7 mg/kg, Imetelstat 9.4 mg/kg
- Where
- 72 sites in United States, Belgium and 9 more
- Volunteers
- 107 people
- Sponsor
- Geron Corporation
Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia
A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and recommended Phase 2 dose (RP2D) of MK-0482. There are 2 parts of this study.
- Trial name
- NCT05038800
- Testing
- MK-0482
- Where
- 5 sites in United States, Israel and 1 more
- Volunteers
- 13 people
- Sponsor
- Merck Sharp & Dohme LLC
Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm
Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN
This is an open-label, multi-center, Phase 1/2 study to determine the MTD and assess the safety, tolerability, PK, immunogenicity, and anti-leukemia activity of IMGN632 when administered as monotherapy to patients with CD123+…
- Trial name
- NCT03386513
- Testing
- IMGN632
- Where
- 29 sites in United States, France and 4 more
- Volunteers
- 179 people
- Sponsor
- AbbVie
Acute Myeloid Leukemia, Essential Thrombocythemia
Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia
The purpose of this study is to determine a safe dose of LY573636-sodium to be given to patients with acute myeloid leukemia and to determine any side effects that may be associated with LY573636-sodium in this patient…
- Trial name
- NCT00718159
- Testing
- LY573636-sodium
- Where
- 5 sites in United States
- Volunteers
- 23 people
- Sponsor
- Eli Lilly and Company